Background {#Sec1}
==========

Breast cancer ranks first among all women's cancers regarding its incidence and rank second among them regarding its cancer-related mortality rate \[[@CR1]\]. Several genetic and environmental factors have been associated with breast cancer risk. Among the most relevant factors is the ability to repair DNA double strand break (DSB). The homologous recombination (HR) and the non-homologous end-joining (NHEJ) pathways have been developed in eukaryotic cells for repair of such defects \[[@CR2]\]. Numerous single nucleotide polymorphisms (SNPs) within genes coding the NHEJ pathway have been associated with breast cancer risk \[[@CR3]\]. More importantly, the mostly recognized breast cancer susceptibility genes *BRCA1* and *BRCA2* participate in the process of HR. Deficiencies in HR have been detected both in *BRCA1*/2 germline mutation--associated and remarkable fraction BRCA1/2 wild-type breast cancer patients \[[@CR4]\]. The *X-ray repair cross-complementing group 3* (*XRCC3*) is an efficient component of HR and is required for the preservation of chromosomal integrity in mammalian cells \[[@CR5]\]. Consequently, it has been regarded as a supposed candidate gene for breast cancer susceptibility. However, the data regarding its participation in breast cancer risk are inconsistent. Hang et al. conducted a meta-analysis of 48 case-control studies (including 14 studies in breast cancer) and reported that *XRCC3* Thr241Met significantly increased risk of breast cancer. However, they suggested that a single larger study should be performed to assess tissue-specific cancer risk in different ethnicities \[[@CR6]\]. Garcı'a-Closas et al. meta-analyzed the studies in Caucasian populations (10,979 cases and 10,423 controls) and reported a weak association between homozygous variants for *XRCC3* Thr241Met and risk of breast cancer. They concluded that this variant is implausible to have a considerable role in breast cancer risk. However, they suggested studies with larger sample sizes to assess probable underlying gene--gene interactions or associations in ethnic-based subgroups \[[@CR7]\]. Lee et al. in their meta-analysis of 12 studies demonstrated that Thr/Met and Met/Met weakly elevated the risk of breast cancer compared to Thr/Thr genotype \[[@CR8]\]. Economopoulos et al. conducted a meta-analysis on 20 case--control studies in non-Chinese individuals and three case--control studies on Chinese individuals and reported association between T allele of this polymorphism (corresponding to Met) and breast cancer risk in recessive model. However, the association was only detected in non-Chinese population \[[@CR9]\]. He et al. reported the mentioned association in recessive and additive models, but suggested conduction of a study with the larger sample size to assess gene-environment interaction \[[@CR10]\]. In another study, He et al. have conducted a meta-analysis of 157 case-control studies including 34 studies in breast cancer (22,917 cases and 24,313 controls) and suggested the *XRCC3* Thr241Met as a susceptibility locus for breast cancer, especially in Caucasians \[[@CR11]\]. Mao et al. demonstrated a significantly higher risk of breast cancer in heterozygote model but not in other models. Such association was significant in Asians. Based on the reported weak association, they suggested conduction of a study with larger sample size \[[@CR12]\]. Finally, using 23 case-control studies, Chai et al. reported association between the mentioned polymorphism and breast cancer risk, especially in Asian populations and in patients without family history of breast cancer \[[@CR13]\].

Therefore, according to inconclusive results of the previous meta-analyses and lack of systematic review in this regard, we conducted a systematic review and meta-analysis to assess the association between the Thr241Met SNP (rs861539) within *XRCC3* and breast cancer risk in diverse inheritance models.

Methods {#Sec2}
=======

Registration {#Sec3}
------------

We conducted the present systematic review protocol according to the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) \[[@CR14]\]. We also registered the study protocol on the international prospective register of systematic review (PROSPERO) network. The registration number was CRD42018104217.

Information source and searching strategy {#Sec4}
-----------------------------------------

We searched PubMed, Scopus, EMBASE, Web of Science and ProQuest databases, the key journals (Breast Cancer Research and Treatment, Cancer Research), conferences/ congress research papers (as Grey literature) and the reference list of the included primary studies until March 2018 T(1990/01/01:2018/03/31) using the following syntaxes: "x-ray repair cross-complementing group 3" or "XRCC3"and"polymorphisms" or "single nucleotide polymorphism" and "breast tumor" or "breast cancer" and "rs861539" or "c.722C \> T" or "p.Thr241Met" or "T241 M" (see Additional file [1](#MOESM1){ref-type="media"}). The complete search syntaxes were developed based on MeSH database and Emtree. The syntaxes for each database are shown in supplementary file. We did not implement any language restriction.

Eligibility criteria and selection process {#Sec5}
------------------------------------------

We included: i) all observational studies such as cross-sectional, case-control and cohort studies ii) studies that assessed associations between Thr241Met within *XRCC3* and breast cancer risk. iii) Studies with available genotype frequencies in both case and control groups. We excluded books, reviews, editorial, letters and articles which did not intend to assess the association between *XRCC3* Thr241Met SNP and breast cancer risk and those without control group data. Our participants are post- or pre-menopause women with breast cancer which is pathologically confirmed. Studies with male breast cancer cases were excluded. Our exposure is rs861539 (T241 M) that was evaluated with various genotyping methods such as PCR-RFLP, Taq-Man, Sequencing and etc. We performed search in the different mentioned sources and exported the search outputs into the End-Note software. The duplicated primary studies were deleted (only one version of the duplicated documents was kept). The screening phase (selecting included/ probable included versus excluded primary studies using the title or/ and the abstract) were performed. The selection or verification process (selecting included versus excluded primary studies) were performed based on the eligibility criteria. All steps for preparing this systematic review such as searching, screening based on titles of papers and abstracts, selection according to examination of full text of articles, risk of bias assessment and data extraction were done independently by two authors (SD and ZTE). Any disagreement regarding the inclusion/exclusion criteria and data extraction were resolved by consensus of the reviewers.

Quality assessment and data extraction {#Sec6}
--------------------------------------

Methodological quality assessment (risk of bias assessment) was based on the Newcastle--Ottawa Scale (NOS). Checklist of each study was filled with two reviewers independently. Any disagreements (between two reviewers) were resolved by the discussion or consensus otherwise opinion of third expert reviewer. For assessing total quality status in primary study we used sum score of quality items. According to this score, we classified the papers in three groups (Good, Fair, Poor) \[[@CR6]\]. Data was extracted by two reviewers as described above. Dataincluded general information of studies, study eligibility, method, risk of bias assessment and results including odds ratio. If there were some unclear information, we contacted with corresponding authors of studies. Our data extraction form includes the following items: First author, Publication year, Source of study participants, Name of Country, Ethnicity, Genotyping method and Reference number. Association between the mentioned polymorphism and breast cancer was evaluated by calculating crude OR based on 2-by-2 table. Furthermore, this association was assessed after controlling potentially confounder variables. For this reason, we extracted adjusted OR values which were calculated by logistic regression in primary studies. Since multi-variable logistic regression models in primary studies were not similar, all adjusted OR values were extracted from primary studies in order to combine similar adjusted OR values in data synthesis step.

Data synthesis (meta-analysis) {#Sec7}
------------------------------

All of data analyses were performed in two distinct groups of familial breast cancer and sporadic breast cancer. Data were analyzed using STATA 13 software. Association between the mentioned SNP and breast cancer risk were analyzed by pooling odds ratio (ORs) with 95% confidence interval (CIs) in three models including dominant (TM + MM vs.TT), recessive (MM vs. TM + TT), and homozygote (MM vs.TT) models using STATA metan module. *Z* test was applied to assess the significance of the ORs, The heterogeneity between included publications was evaluated using I^2^ parameter as described previously \[[@CR14]\] where the higher values indicate higher level of heterogeneity. Furthermore, we checked heterogeneity by the chi-square-based Q-test (Heterogeneity was considered statistically significant if *p* \< 0.05) (Egger et al., 1997). We combined genotype frequencies to calculate univariable (crude) OR. In addition, combination of adjusted OR values was based on the similarity of adjusted OR values restricted in two models including age-adjusted (association between rs861539 and breast cancer after controlling age of patients) and age and other factors. The random-effects model was used to combine parameters acquired from discrete studies due to methodological variation. Sensitivity analyses were performed using leave-one-out sensitivity analysis to indicate the effect of the quality score on the results. Subgroup analyses were done for evaluating potential sources of heterogeneity based on ethnicity, case selection methods case group (hospital vs. population), methodological quality status (Good, Fair, Poor) and-case enrollment strategies (incident vs. prevalent).

Publication bias {#Sec8}
----------------

Funnel plots, Begg's and Egger's test were used to measure publication bias (*p*-value\< 0.1) \[[@CR6], [@CR11]\].

Results {#Sec9}
=======

Literature search {#Sec10}
-----------------

Figure [1](#Fig1){ref-type="fig"} shows the data collection flow diagram for the present study. At the first step of database search, 4795 items were obtained. The initial screening and removal of duplicate items led to identification of 287 publications. Further screening resulted in removal of 187 items. Finally, full texts of the remained items were assessed for eligibility and 55 publications containing 30,966 sporadic breast cancer cases, 1174 familial breast cancer cases and 32,890 controls were included in the syntheses \[[@CR8], [@CR15]--[@CR57]\]. Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} show the features of selected studies which assessed the association between the mentioned SNP and breast cancer in familial and sporadic cases respectively.Fig. 1PRISMA flow diagram showing the selection of the 55 eligible case control studiesTable 1General characteristics of studies reporting associations in familial breast cancer (HB: hospital based, PB: population based, N/M: Not mentioned, HWE: Hardy-Weinberg Equilibrium, NOS: The Newcastle-Ottawa Scale, Quality of studies based on NOS star scoring system: 1--2 stars: poor, 3--5 stars: fair and 6--10 stars: good)First AuthorYearSocietyCountryEthnicityGenotyping MethodCase-enrollment strategyFrequency in CasesFrequency in ControlsHWENOS scoreTTTMMMTotalTTTMMMTotalCosta2007HBPortugalCaucasianPCR-RFLPPrevalent402912812251406643105Dufloth2005HBBrazilMixedPCR-RFLPPrevalent27187526835151180.0053Figueiredo2004PBCanadaCaucasianMALDI-TOF MSIncident2938168313204370.3419Forsti2004PBFinlandCaucasianPCR-RFLPPrevalent7285151728988252020.6544Smith b2003HBUSACaucasianPCR-RFLPIncident1014327425524121\> 0.057Vral2011HBItalyCaucasianPCR-RFLP or SnapShot techniqueN/M6087231705484301680.9642Gonzalez-Hormazabal2012PBChileMixedTaq-ManPrevalent18710332322335209235670.1777Jara2010PBChileMixedConformation-sensitive gel electrophoresis (CSGE)Prevalent1499127267296182225000.528Table 2General characteristics of studies reporting associations in sporadic breast cancer (HB: hospital based, PB: population based, HWE: Hardy-Weinberg Equilibrium, NOS: The Newcastle-Ottawa Scale)First AuthorYearSocietyCountryEthnicityGenotyping MethodCase-enrollment strategyFrequency in CasesFrequency in ControlsHWENOS\
ScoreTTTMMMTotalTTTMMMTotalAl Zoubi2015HBJordanArabSequencingPrevalent16264468185310.335Al Zoubi2017HBItalyCaucasianSequencingPrevalent813223492150.725Ali2016HBSaudi ArabianArabPCR-RFLPIncident43732714332327835\>  0.056Brooks2008PBUSAMixedPCR-RFLPIncident25425998611249286766110.6619Costa2007HBPortugalCaucasianPCR-RFLPPrevalent687731176121612921105Devi2017HBIndiaAsianPCR-RFLPPrevalent350100144644269995340.2510Ding2015HBChinaAsianPCR-LDRPrevalent5109156065577426330.257Dufloth2005HBBrazilMixedPCR-RFLPPrevalent15162336835151180.0053Figueiredo2004PBCanadaCaucasianMALDI-TOF MSincident11014861319133180523650.399Forsti2004PBFinlandCaucasianPCR-RFLPPrevalent1118032223161110272980.6544Garcia-Closas2006PBPolandCaucasianNAIncident7859072821974980103926622850.7097Garcia-Closas2006PBUSACaucasianNAIncident110214194572978973121336825540.7487Gohari-Lasaki2015HBIranMixedPCR-RFLPPrevalent70131710069229100NA2Han2004PBUSAMixedTaq-ManIncident38842913595246860717012450.2258Jacobsen2003PBDenmarkCaucasianTaq-Man / PCR-RFLPIncident16320359425160198654230.7724Kipen2017HBBelarusCaucasianPCR-RFLPIncident86681516984947185\>  0.055Krupa2009HBPolandCaucasianPCR-RFLPPrevalent29683813529107391750.0034Kuschel2002PBUKCaucasianTaq-ManIncident7901026327214372882722917840.84Lavanya2015HBIndiaAsianPCR-RFLPN/M427150408250\> 0.056Lee2007HBSouth KoreaAsianSingle base extension assayPrevalent4375114893492903780.746Loizidou2008PBCyprusMixedPCR-RFLPIncident312560220109235160022611770.2858Millikan2005PBUSACaucasianTaq-ManIncident505578171125443555514211320.0869Millikan2005PBUSAAfrican-AmericanTaq-ManIncident48222241745421211446760.0159Ozgoz2017HBTurkeyMixedMultiplex-PCR & MALDI-TOFPrevalent4246141023740231000.2347Qureshi2014HBPakistanMixedPCR-RFLPPrevalent746715156101445105\>  0.056Rafii2003HBUKCaucasianTaq-ManPrevalent201248725213414161298860.878Ramadan2014HBEgyptMixedPCR-RFLPIncident28571510030378750.4917Romanowicz2017HBPolandCaucasianHRMPrevalent4872802005272762000.8626Romanowicz-Makowska2012HBPolandCaucasianPCR-RFLPPrevalent2103701807601783662167600.3435Romanowicz-Makowska2011HBPolandCaucasianPCR-RFLPPrevalent2203781927901883842267980.9395Sangrajrang2007HBThaiAsianMelting curve analysisIncident4376915073843824240.3226Santos2010HBBrazilMixedPCR-RFLPIncident283166549297850.376Shadrina2016PBRussiaCaucasianTaq-ManPrevalent28528495664294278726440.596Silva2010HBPortugalCaucasianPCR-RFLPN/M10913842289178276945480.466Smith2008HBUSACaucasianMass ARRAY systemIncident12413754315158184594010.6495Smith2008HBUSAAfrican-AmericanMass ARRAY systemIncident321915248205730.1697Smith a2003HBUSACaucasianPCR-RFLPIncident9610551252104129352680.6117Smith b2003PBUSACaucasianPCR-RFLPIncident304017873955151090.687Smolarz2015HBPolandCaucasianPCR-RFLPPrevalent19351670153520700.7186Sobczuk2009HBPolandCaucasianPCR-RFLPPrevalent2971501502450321060.5675Sterpone2010HBItalyCaucasianPCR-RFLPPrevalent182144315154340.8536Su2015HBTaiwanAsianPCR-RFLPPrevalent10521413912321131871412320.897Thyagarajan2006PBUSACaucasianPCR-RFLPN/M16019267419126157403230.4058Vral2011HBItalyCaucasianPCR-RFLP or SnapShotN/M13229445484301680.9642Webb2005PBAustraliaCaucasianTaq-ManPrevalent5006121841296248321916600.4258Webb2005PBAustraliaMixedTaq-ManPrevalent9144141495954151280.6258Zhang2005HBChinaAsianPCR-RFLPIncident3380107220291151663100.173BCAC HBBCS2006HBGermanyCaucasianTaq-Man & ARMSN/M951194211567788291940.645BCAC Madrid2006HBSpainCaucasianTaq-Man & IlluminaN/M255274926212812871056730.0286BCAC SEARCH2006PBUKCaucasianTaq-ManN/M1177146246531041607189854940540.769BCAC Seoul2006HBKoreaAsianTaq-Man & SNPstreamN/M5025315563553103860.4118BCAC Sheffield2006HBUKCaucasianTaq-ManN/M458555168118143753419511660.1447BCAC USRTS2006PBUSACaucasianTaq-ManN/M2813369871540248015510370.557

Meta-analysis results {#Sec11}
---------------------

Initially, we conducted the analysis in the familial and sporadic studies after using the random-effects model. Random model was used for analysis of associations in three inheritance models based on its more conservative nature. Final results for familial and sporadic studies are shown in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}.Table 3Meta-analysis of studies reporting sporadic cases in different subgroupsPotentialOdd Ratio\
(CI 95%)No of StudiesHeterogeneity χ^2^P valueI^2^Interaction p valueA Homozygote model: MM vs. TTEthnicityCaucasian0.922 (0.838--1.016)3163.020.00052.4%0.0001Asian0.725 (0.345--1.522)818.890.00962.9%African-American1.278 (0.826--1.977)20.770.3810.0%Arab3.649 (2.029--6.563)20.260.6090.0%Mixed0.889 (0.694--1.140)1016.490.00945.4%Study-basedHospital-based0.979 (0.825--1.162)3681.660.00057.1%0.655Population-based0.869 (0.796--0.950)1726.220.05139.0%Methodological qualityGood0.974 (0.786--1.208)1536.700.00161.9%0.891Fair0.930 (0.830--1.041)3684.070.00058.4%Poor0.644 (0.338--1.229)20.370.5440.0%Case enrollment strategiesIncident0.938 (0.819--1.075)2054.880.00059.9%0.455Prevalent0.887 (0.720--1.093)2345.700.00158.4%Not mentioned0.975 (0.798--1.191)1021.530.01158.2%All studies0.937 (0.849--1.034)53124.200.00058.1%--B Dominant model: TM + MM vs. TTEthnicityCaucasian1.022 (0.969--1.079)3143.650.05131.3%0.0001Asian1.296 (1.027--1.636)818.220.01161.6%African-American0.921 (0.749--1.134)20.530.4650.0%Arab0.671 (0.419--1.074)20.000.9500.0%Mixed1.084 (0.863--1.361)1033.910.00073.5%Study-basedHospital-based1.089 (0.975--1.215)3689.810.00061.0%0.655Population-based1.017 (0.955--1.084)1731.380.01249.0%Methodological qualityGood1.028 (0.950--1.112)1536.880.00162.0%0.891Fair1.050 (1.010--1.091)3684.160.00058.4%Poor1.022 (0.643--1.624)20.120.7250.0%Case enrollment strategiesIncident1.011 (0.934--1.095)2037.530.00749.4%0.455Prevalent1.111 (0.958--1.289)2374.400.00070.4%Not mentioned1.042 (0.975--1.113)107.890.5450.0%All studies1.045 (0.982--1.112)53121.390.00057.2%--C Recessive model: MM vs. TM + TTEthnicityCaucasian0.921 (0.849--1.000)3156.420.00246.8%0.000Asian0.688 (0.374--1.266)815.510.03054.9%African-American1.265 (0.778--2.055)21.020.3122.2%Arab3.649 (2.029--6.563)21.550.21335.4%Mixed0.895 (0.728--1.101)1013.930.12535.4%Study-basedHospital-based0.989 (0.844--1.159)3690.430.00061.3%0.00Population-based0.868 (0.806--0.934)1721.790.15026.6%Methodological qualityGood0.961 (0.822--1.125)1527.190.01848.5%0.153Fair0.942 (0.841--1.055)3699.370.00064.8%Poor0.645 (0.355--1.173)20.840.3590.0%Case enrollment strategiesIncident0.950 (0.823--1.097)2063.030.00069.9%0.377Prevalent0.900 (0.761--1.064)2345.190.00351.3%Not mentioned0.974 (0.812--1.168)10210.01357.1%All studies0.939 (0.857--1.029)55131.150.00060.3%--Table 4Meta-analysis of studies reporting familial cases in different subgroupsPotentialOdd Ratio\
(CI 95%)No of StudiesHeterogeneity χ^2^*P* valueI^2^Interaction *p* valueA Homozygote model: MM vs. TT EthnicityCaucasian1.204 (0.835--1.735)52.560.6340.0%0.000Mixed0.451 (0.309--0.659)31.80.4060.0% Study-basedHospital-based1.184 (0.784--1.788)41.520.6770.0%0.690Population-based0.581 (0.318--1.060)48.240.04163.6% Methodological qualityGood1.080 (0.691--1.688)30.670.7160.0%0.002Fair0.504 (0.304--0.834)44.510.21133.5%Poor1.449 (0.752--2.793)10.00..% Case enrollment strategiesIncident1.000 (0.300--3.327)21.640.20138.9%0.068Prevalent0.683 (0.412--1.134)510.690.03062.6%Not mentioned1.449 (0.752--2.793)10..% All studies0.809 (0.521--1.258)817.70.01360.4%--B Dominant model: TM + MM vs. TT EthnicityCaucasian1.012 (0.800--1.280)50.820.9360.0%0.576Mixed1.104 (0.909--1.341)30.390.8240.0% Study-basedHospital-based1.016 (0.770--1.341)41.110.7750.0%0.690Population-based1.087 (0.910--1.299)40.250.9690.0% Methodological qualityGood1.132 (0.855--1.499)30.130.9370.0%0.614Fair1.075 (0.887--1.304)40.41. 0.9370.0%Poor0.868 (0.553--1.364)10.00..% Case enrollment strategiesIncident0.958 (0.530--1.733)20.390.20138.9%0.579Prevalent1.104 (0.936--1.302)50.030.8560.0%Not mentioned0.868 (0.553--1.364)10..% All studies1.066 (0.917--1.238)81.520.9820.0%--C Recessive model: MM vs. TM + TT EthnicityCaucasian1.233 (0.877--1.732)5**3.41**0.4910.0%0.576Mixed0.462 (0.298--0.716)32.650.26624.5% Study-basedHospital-based1.224 (0.834--1.796)41.250.7420.0%0.690Population-based0.409 (0.228--0.734)410.890.01272.4% Methodological qualityGood1.172 (0.765--1.793)30.790.6750.0%0.614Fair0.515 (0.297--0.894)45.630.13146.7%Poor1.389 (0.770--2.508)10.00. 2.508-- Case enrollment strategiesIncident0.977 (0.258--3.707)514.050.00771.5%0.579Prevalent0.718 (0.410--1.257)22.360.12457.7%Not mentioned1.389 (0.770--2.508)10.00---- All studies0.831 (0.524--1.319)821.530.00367.5%--Bold entry is significant

The forest plots for each model are depicted in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}.Fig. 2Forest plots of *XRCC3* Thr241Met polymorphism and sporadic breast cancer for all eligible studies. **a** Homozygote model: MM vs. TT. **b** Dominant model: TM + MM vs. TT. **c** Recessive model: MM vs. TM + TTFig. 3Forest plots of *XRCC3* Thr241Met polymorphism and familial breast cancer for all eligible studies. **a** Homozygote model: MM vs. TT. **b** Dominant model: TM + MM vs. TT. **c** Recessive model: MM vs. TM + TT

No significant associations were detected between the mentioned SNP and breast cancer risk in any inheritance model either in familial or in sporadic breast cancer cases.

Next, we assessed association between this SNP and risk of familial or sporadic breast cancer in ethnic-based subgroups (Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}). In sporadic breast cancer, the SNP was associated with breast cancer risk in Arab populations in homozygous (OR (95% CI) = 3.649 (2.029--6.563), *p* = 0.0001) and recessive models (OR (95% CI) = 4.092 (1.806--9.271), *p* = 0.001). However, the association was significant in Asian population in dominant model (OR (95% CI) = 1.296 (1.027--1.636), *p* = 0.029). Based on the calculated Interaction *p*-value in ethnic-based subgroup analyses (p = 0.0001), we conclude that such subgroup analysis strategy was appropriate and the calculated ORs are significant. However, the associations was significant in familial breast cancer in mixed ethnic-based subgroup in homozygote and recessive models (OR (95% CI) = 0.451 (0.309--0.659), *p* = 0.0001, OR (95% CI) = 0.462 (0.298--0.716), *p* = 0.001 respectively).Fig. 4Forest plots of *XRCC3* Thr241Met polymorphism and risk of sporadic breast cancer in ethnic-based subgroups. **a** Homozygote model: MM vs. TT. **b** Dominant model: TM + MM vs. TT. **c** Recessive model: MM vs. TM + TTFig. 5Forest plots of *XRCC3* Thr241Met polymorphism and risk of familial breast cancer in ethnic-based subgroups. **a** Homozygote model: MM vs. TT. **b** Dominant model: TM + MM vs. TT. **c** Recessive model: MM vs. TM + TT

Subsequently, we appraised the associations based on the study-base for selecting case/control (society) subgroup (hospital-based vs. population-based). In sporadic cases, the associations were significant in population-based studies in homozygote and recessive models (OR (95% CI) = 0.869 (0.796--0.950), *p* = 0.002 and OR (95% CI) = 0.868 (0.806--0.934), *p* = 0.0001 respectively). The Interaction *p*-value was calculated as 0.655 which shows inappropriateness of such subgroup analysis strategy. No significant associations were found in society-based analysis in familial cases (Additional file [2](#MOESM2){ref-type="media"}: Figure S1 and Additional file [3](#MOESM3){ref-type="media"}: Figure S2).

We also assessed the associations in methodological quality subgroups (Based on NOS scores) and found no significant association in sporadic (Interaction *p*-value = 0.891) but in familial cases we found the association in studies with fair quality in homozygote and recessive models (OR (95% CI) = 0.504 (0.304--0.834), *p* = 0.008, OR (95% CI) = 0.515 (0.297--0.894), *p* = 0.018 respectively) (Additional file [4](#MOESM4){ref-type="media"}: Figure S3 and Additional file [5](#MOESM5){ref-type="media"}: Figure S4).

Finally, we evaluated associations based on the case enrollment strategy (Incident vs. Prevalent). No significant associations were detected either in sporadic or familial cases (Interaction p-value = 0.22) (Additional file [6](#MOESM6){ref-type="media"}: Figure S5 and Additional file [7](#MOESM7){ref-type="media"}: Figure S6).

Publication bias {#Sec12}
----------------

We conducted both Begg's funnel plot and Egger's test for appraisal of the publication bias in sporadic and familial studies separately. The calculated parameters are shown in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. Moreover, the outlines of the funnel plots were rather symmetric implying absence of any significant publication bias (Figs. [6](#Fig6){ref-type="fig"} and [7](#Fig7){ref-type="fig"}).Fig. 6Funnel plots for whole publications in sporadic cases. **a** Dominant model: TM + MM vs.TT. **b** Recessive model: MM vs. TM + TT. **c** Homozygote model: MM vs.TTFig. 7Funnel plots for whole publications in familial cases. **a** Dominant model: TM + MM vs.TT. **b** Recessive model: MM vs. TM + TT. **c** Homozygote model: MM vs.TT

Adjusted OR {#Sec13}
-----------

As we did not detected any association between the mentioned SNP and breast cancer risk in crude analysis, we subsequently assessed associations considering the effects of confounder variables using adjusted ORs. We retrieved adjusted ORs and confounder variables from the publications. Subsequently, we categorized confounder variables to two groups: 1. Age 2. Other variables including body mass index, smoking, hazardous life style and contraceptive use. Analyses were performed in sporadic subgroup based on the three inheritance models (Fig. [8](#Fig8){ref-type="fig"}). There was no significant association between this SNP and risk of sporadic breast cancer in any inheritance model considering adjusted ORs.Fig. 8Forest plots for adjusted OR (adjusted for Age and Other variables including body mass index, smoking, hazardous life style and contraceptive use.) in sporadic cases. **a** Dominant model: TM + MM vs.TT. **b** Recessive model: MM vs. TM + TT. **c** Homozygote model: MM vs.TT

Sensitivity analysis and cumulative meta-analysis {#Sec14}
-------------------------------------------------

To assess the strength of the association results, we conducted a leave-one-out sensitivity analysis by repeatedly removing one study at a time and re-measuring the summary OR. The summary ORs did not change, showing that our results were not originated from any certain study (Table [1](#Tab1){ref-type="table"}).

Discussion {#Sec15}
==========

In the present meta-analysis, we assessed the associations between Thr241Met SNP and familial/ sporadic breast cancer based on the results of 55 studies containing 30,966 sporadic breast cancer cases, 1174 familial breast cancer cases and 32,890 controls. Crude analyses revealed no associations. In spite of assessing potential confounder variables and adjusting odds ratio of the primary studies, we did not find any association.

In sporadic cases, the narrow confidence intervals indicate the high power of the meta-analysis, so the results are conclusive. However, in familial cases, the wide confidence intervals imply that further studies are needed to reach conclusive results. Based on such findings, we predict that inclusion of further studies would not change the results of the meta-analysis. Sensitivity analyses by repeatedly removing one study at a time showed that the results of crude analysis were consistent result, therefore signifying the robustness of the study according to sensitivity analysis results, no relation between quality of studies with results and non-considerable publication bias.

Another strong point of our study was that we considered adjusted ORs to control the effects of confounding variables. Such approach further verified our results.

Through calculation of Interaction *p* values we determined subgroup analysis based on ethnicity as being the most strategy in this regard. Ethnic based analysis showed that in sporadic breast cancer, the SNP was associated with breast cancer risk in Arab and Mixed populations in homozygous and recessive models. The association was significant in Asian population in dominant model. However, no associations were detected in familial breast cancer in any ethnic-based subgroup and any inheritance model. The detected associations between this SNP and risk of sporadic breast cancer in certain populations had wide confidence intervals which necessitate extra studies. The same situation has been seen in familial breast cancer cases in ethnic-based subgroup analyses.

Chai et al. have performed a meta-analysis of 23 case-controls studies on association between Thr241Met SNP and breast cancer. Their meta-analysis of the pooled data of 13,513 cases and 14,100 controls association between the mentioned SNP and breast cancer risk in recessive and homozygote models in total populations as well as within Asian populations \[[@CR14]\]. Our study had the advantage of including higher numbers of cases and controls and assessment of adjusted ORs and sensitivity analysis. The results of our ethnic-based analysis were consistent with their results regarding the observed association in Asian population but not regarding the associated model. Although they found association between this SNP and risk of sporadic breast cancer, we disapprove such association based on the obtained conclusive results.

In brief, we have implemented the high quality systematic review and meta-analysis including comprehensiveness (inclusion of 5 databases), inclusion of grey literature (theses) and duplicate implementation of all steps of systematic review and meta-analysis (independent implementation of search, screening, selection, quality assessment and data extraction by two authors). In addition, priori principle (establishment and registration of protocol) was applied.

Our study had some limitations. Based on the unavailability of sufficient data from the primary studies, we could not assess the association between the mentioned SNP and breast cancer risk in pre−/post-menopause subgroups. In addition, the adjusted OR values of the primary studies were based on different parameters which might influence the validity of this kind of statistical analysis. Finally, there were some limitations in the primary studies and we did not find any genotyping data according to breast cancer subtypes except for 3 studies in triple negative breast cancer. Due to the low number of primary studies, the result of meta-analysis based on breast cancer subtypes was not reliable. So, we did not performed this type of analysis.

Conclusion {#Sec16}
==========

Taken together, our results in a large sample of both sporadic and familial cases of breast cancer showed insignificant role of Thr241Met in the pathogenesis of this type of malignancy. Such results were more conclusive in sporadic cases. In familial cases, future studies are needed to verify our results.
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CIs

:   95% confidence intervals

DSB

:   DNA double strand break

HB

:   Hospital based

HR

:   Homologous recombination

HWE

:   Hardy-Weinberg Equilibrium

NHEJ

:   Non-homologous end-joining

NOS

:   Newcastle--Ottawa Scale

ORs

:   Crude odds ratios

PB

:   Population based

SNP

:   Single-nucleotide polymorphism

*XRCC3*

:   *X-ray repair cross-complementing group 3*
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